Unichem Laboratories profit and loss

Latest FY26

Revenue: ₹2,202cr+4.3% on FY25
EBITDA: ₹184cr−30.5% on FY25
Net profit: ₹253cr+83.9% on FY25
EPS: ₹35.91+83.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,308	2,202	2,111	1,705	1,343	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	71.9	63.1	35.3	31.6	38.5
	2,380	2,265	2,146	1,736	1,382
	741	769	888	743	532
	248	232	176	0.9	1.5
	75.0	20.2	−200	−79.1	17.2
	396	397	402	393	356
	31.7	31.6	21.0	22.7	17.3
	123	125	125	113	113
	620	601	580	547	481
	2,234	2,174	1,992	1,741	1,519
	229	184	265	100	−45.6
	105	59.1	140	−13.0	−159
Profit
	145	90.5	155	−4.1	−138
	205	202	0.0	−57.6	−38.6
	350	292	155	−61.7	−176
	3.3	4.0	18.3	7.9	10.5
	42.3	35.5	−1.2	0.9	15.3
	45.6	39.5	17.1	8.8	25.9
	305	253	138	−70.5	−202
	305	253	138	−70.5	−202
	5.9	12.0	−7.0	−5.5	45.9
	311	265	131	−75.9	−156
	—	253	138	−70.5	—
Per share
	₹44.01	₹35.91	₹19.53	−₹10.01	−₹28.72
	₹43.94	₹35.85	₹19.47	−₹10.01	−₹28.72
Other comprehensive income — detail
	5.9	12.0	−7.0	—	—
	5.6	10.2	1.4	−0.3	18.1
	2.6	2.6	0.0	—	—
	—	—	—	0.0	−20.6
	2.9	4.4	−8.4	−5.2	7.2
Per share — as-filed variants
	₹44.01	₹35.91	₹19.53	−₹10.01	−₹28.72
	₹43.94	₹35.85	₹19.47	−₹10.01	−₹28.72
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,244	1,181	1,247	1,040	792
	53.9%	53.7%	59.1%	61.0%	59.0%
Adjusted (ex-exceptional items) — derived
	145	90.5	155	−4.1	−138
	205	202	0.0	−57.6	−38.6
	127	78.3	138	−12.9	−164
	₹18.27	₹11.12	₹19.53	−₹1.83	−₹23.24

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersGUFICBIO RPGLIFE GUJTHEM SMSPHARMA ORCHPHARMA INDSWFTLAB SOLARA FDCMcap ₹3,441 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,343.0	1,704.9	2,111.0	2,201.9	2,307.9
Other Income	38.5	31.6	35.3	63.1	71.9
Total Income	1,381.5	1,736.5	2,146.3	2,264.9	2,379.7
Expenses
+ Cost of Materials Consumed	532.2	742.8	888.2	768.8	741.4
+ Purchases of Stock-in-Trade	1.5	0.9	175.8	231.5	247.8
+ Changes in Inventories	17.2	-79.1	-200.4	20.2	75.0
+ Employee Benefit Expense	356.4	393.1	402.2	396.6	395.6
+ Finance Costs	17.3	22.7	21.0	31.6	31.7
+ Depreciation & Amortisation	113.4	113.2	124.6	125.1	123.3
+ Other Expenses	481.2	547.0	580.2	600.5	619.6
Total Expenses	1,519.3	1,740.5	1,991.7	2,174.4	2,234.2
EBITDA	-45.6	100.2	264.9	184.2	228.6
EBIT	-159.0	-13.0	140.3	59.1	105.3
Profit
PBT before Exceptional Items	-137.8	-4.1	154.6	90.5	145.5
+ Exceptional Items	-38.6	-57.6	0.0	201.9	204.9
Pretax Income	-176.4	-61.7	154.6	292.4	350.4
+ Current Tax	10.5	7.9	18.3	4.0	3.3
+ Deferred Tax	15.3	0.9	-1.2	35.5	42.3
Tax Expense	25.9	8.8	17.1	39.5	45.6
Net Income	-202.2	-70.5	137.5	252.8	304.8
+ Net Income — Continuing Ops	-202.2	-70.5	137.5	252.8	304.8
+ Other Comprehensive Income	45.9	-5.5	-7.0	12.0	5.9
Total Comprehensive Income	-156.3	-75.9	130.6	264.8	310.7
Net Income to Common	—	-70.5	137.5	252.8	—
Per Share
Basic EPS	-28.72	-10.01	19.53	35.91	44.01
Diluted EPS	-28.72	-10.01	19.47	35.85	43.94
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-7.0	12.0	5.9
+ Items NOT to be Reclassified to P&L	18.1	-0.3	1.4	10.2	5.6
+ Tax on Items NOT to be Reclassified	—	—	0.0	2.6	2.6
+ Tax on Items NOT to be Reclassified — alt tag	-20.6	0.0	—	—	—
+ Items to be Reclassified to P&L	7.2	-5.2	-8.4	4.4	2.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	-28.72	-10.01	19.53	35.91	44.01
Diluted EPS — Continuing Operations	-28.72	-10.01	19.47	35.85	43.94
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	792.1	1,040.3	1,247.3	1,181.3	1,243.8
Gross Margin %	58.98	61.02	59.09	53.65	53.89
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-137.8	-4.1	154.6	90.5	145.5
− Exceptional Items (reconciliation)	-38.6	-57.6	0.0	201.9	204.9
Net Income Adj (tax-effected)	-163.7	-12.9	137.5	78.3	126.6
EPS Adj	-23.24	-1.83	19.53	11.12	18.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	14.1	14.1	14.1	14.1	14.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.